Allotera Therapeutics
Latest round
- Series C
Last raised
- Jul 2026
Total raised
- $222M
Investors
- 13
About Allotera Therapeutics
Based in Missouri, US, and founded in 2018, Wugen Inc. develops immuno-oncology cell therapies for tumors and heme malignancies. The company was co-founded by Dr. Todd Fehniger, Dr. John DiPersio, Dr. Melissa Berrien-Elliott, and Dr. Matthew Cooper, its Chief Scientific Officer. Dan Kemp is the current President and CEO of the company. In July 2026, Wugen Inc. The company's therapies aim to treat patients with cancer. The company is employing its patented technologies to manufacture WU-NK-101, a treatment for acute myelogenous leukemia that is currently in clinical trials (AML). It is also working on a pipeline of products aimed at solid tumor indications. Wugen Inc. plans to advance the clinical development of its NK Cell Platform and initiate studies on solid tumor indications.
Who invested in Allotera Therapeutics
13 investors across 3 rounds
See all investors in Allotera Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Allotera Therapeutics
Who invested in Allotera Therapeutics?
Allotera Therapeutics has 13 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Allotera Therapeutics raised?
Allotera Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Allotera Therapeutics last raise money?
Allotera Therapeutics's most recent round on record is a Series C, in Jul 2026.
What does Allotera Therapeutics do?
Based in Missouri, US, and founded in 2018, Wugen Inc.
Where is Allotera Therapeutics headquartered?
Allotera Therapeutics is headquartered in St. Louis, US.
Which VCs invest in companies like Allotera Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Allotera Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Allotera Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.